Lunit Secures Multi-Year Contract with UAE's Largest Healthcare Network to Power National AI Breast Cancer Screening Program
Strategic agreement to deploy Lunit INSIGHT MMG across SEHA's extensive healthcare network, analyzing over hundred thousand mammograms over five years SEOUL, South Korea, March 18, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and t...
World's First Large-Scale, Multicenter Prospective Study in Single-Reading Mammography Confirms Lunit AI Boosts Cancer Detection
Prospective study finds Lunit AI increases cancer detection by 13.8% in single-reader settings without raising recall rates, presenting a game-changing tool for countries relying on single-reader mammography screening SEOUL, South Korea, March 10, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a le...
Lunit Expands Partnership with Saudi Arabia's Largest Medical Group to Deploy AI Chest X-Ray Solution
Following last year's success, Lunit secures a second contract with Dr. Sulaiman Al Habib Medical Group, analyzing 1 million chest X-rays over three years SEOUL, South Korea, March 6, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics an...
Lunit Achieves Milestone at ECR 2025: 13 Oral Presentations Among 15 AI Studies, Demonstrating Unmatched Clinical Impact
* Lunit to present 15 studies, with an unprecedented 13 accepted as oral presentations, marking a significant milestone in AI-powered radiology research * Key studies demonstrate AI's capability to replace one radiologist in double reading, detect subclinical breast cancer years in advance, an...
Lunit Announces Leadership Transition at Volpara: Craig Hadfield Appointed CEO
SEOUL, South Korea and WELLINGTON, New Zealand, Feb. 26, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the appointment ofCraig Hadfield as the new CEO of its subsidiary, Volpara Health Technologies. ...
Lunit Partners with SITC to Launch Exclusive Research Program Featuring Advanced AI Technology for SITC Members
Lunit SCOPE® IO now available to SITC members for AI-powered TME profiling, in a collaborative effort to advance cancer immunotherapy SEOUL, South Korea, Feb. 3, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has en...
Lunit AI Enhances Precision in Predicting Outcomes for HER2-Targeted Therapy in Metastatic Colorectal Cancer - new study published in JCO Precision Oncology
Newly published study in collaboration with Japan's NCCHE reveals how AI-powered HER2 and tumor microenvironment analysis improves patient stratification and clinical outcome predictions SEOUL, South Korea, Jan. 23, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered sol...
New Lunit Study Demonstrates Universal AI Model for Analysis of Immunohistochemistry Images
Research in npj Precision Oncology highlights multi-cohort training approach and accurate analysis of unseen immunohistochemistry data SEOUL, South Korea, Dec. 12, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, toda...
Lunit Marks Go-Live in Groundbreaking National AI Cancer Screening Program in BreastScreen NSW
Lunit INSIGHT MMG integrated into the clinical workflow of Australia's BreastScreen New South Wales to assist in reading approximately 31,000 mammography exams annually SEOUL, South Korea, Dec. 9, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer d...
Lunit and Volpara Unveiled Unified Ecosystem at RSNA 2024 to Transform Global Cancer Care
Lunit and Volpara revealed a unified Ecosystem at RSNA 2024, featuring AI-powered cancer risk prediction, autonomous report generation, and innovations to transform global cancer care SEOUL, South Korea, Dec. 5, 2024 /PRNewswire/ -- At this year's RSNA 2024 Annual Meeting, Lunit (KRX:328130.KQ),...
Real-World Validation: Lunit AI Proven Successful in 1-Year Breast Cancer Screening Deployment
Follow-up to ScreenTrustCAD presented at RSNA 2024 highlights 1-year post-AI adoption success in improving cancer detection, radiologist workload, and screening efficiency SEOUL, South Korea, Dec. 2, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cance...
Lunit Inks Partnership with Salud Digna to Advance AI in Medical Imaging
* AI-powered chest X-ray and mammography analysis solutions to be deployed across one ofMexico's largest healthcare networks SEOUL, South Korea, Nov. 27, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announc...
Lunit to Showcase Research Contributions at RSNA 2024 with Record-Breaking 20 Abstracts
Twenty studies validate AI performance across diverse populations and clinical settings, including award-winning research in emergency radiology SEOUL, South Korea, Nov. 25, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeu...
Lunit Announces Collaboration with AstraZeneca to Develop AI-Powered Digital Pathology Risk Assessment Tools for NSCLC
Collaboration to harness Lunit SCOPE Genotype Predictor for rapid and convenient prediction of non-small cell lung cancer driver mutations SEOUL, South Korea, Nov. 18, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, ...
Lunit Partners with VIDI Group to Deliver AI-Powered Mammography to France's Largest Radiology Network
Agreement to make Lunit INSIGHT MMG accessible to over 400 sites across France SEOUL, South Korea, Nov. 13, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a strategic alliance with VIDI Group, the lar...
Lunit Shows Promise of AI in Predicting Immunotherapy Response for Rare Cancer Patients at SITC 2024
Study reveals potential of AI-powered tumor microenvironment assessment in predicting treatment outcomes in rare cancer patients receiving pembrolizumab SEOUL, South Korea, Nov. 8, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and t...
Lunit AI Predicts Breast Cancer Risk Up to 6 Years in Advance
* Two new studies show Lunit INSIGHT MMG cuts radiologist workload by 50% in a double reading environment while maintaining or improving screening quality, and predicts cancer risk up to six years in advance SEOUL, South Korea, Oct. 23, 2024 /PRNewswire/ -- Amid rising demands and a global shor...
Lunit to Present AI-Analyzed Immune Phenotype Study as Immunotherapy Response Predictor for Advanced Gastric Cancer at ESMO Congress 2024
* Lunit SCOPE IO® demonstrates potential to assess immune phenotype as an AI-powered biomarker for predicting efficacy of Nivolumab plus Chemotherapy in advanced gastric cancer, independent of PD-L1 status SEOUL, South Korea, Sept. 10, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provi...
Lunit Joins Roche's Digital Pathology Open Environment to Advance Cancer Biomarker Testing
* Lunit's AI-powered biomarker, Lunit SCOPE PD-L1 TPS, integrates into Roche's navify® Digital Pathology platform to enhance precision medicine and improve cancer biomarker testing SEOUL, South Korea, Sept. 9, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solution...
Immune Phenotyping Identified as Promising Predictive Biomarker by Lunit AI in Biliary Tract Cancer - New publication in CCR
* AI-based tumor microenvironment classification utilizing Lunit SCOPE IO® shows promise for guiding treatment decisions in advanced BTC SEOUL, South Korea ,Sept. 3, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, to...
